Nov 06, 2024 / 01:45PM GMT
Operator
Good day. And thank you for standing by Welcome to the Arbutus BioPharma 2024 3rd quarter, financial results and corporate update.
(Operator Instructions) I would now like to hand the conference over to your first speaker today, Lisa Capparelli, Vice President of Investor Relations. Please go ahead.
Lisa Capparelli - Arbutus Biopharma Corp - Investor Relations
Thank you, Antoine. Good morning, everyone and thank you for joining arbutus' third quarter, 2024 financial results and corporate update call. Joining me today from the Arbutus executive team are Michael McElhaugh, interim President and Chief Executive Officer David Hastings, Chief Financial Officer, Dr Karen Sims, Chief Medical Officer and Michael Sofia, Chief Scientific Officer, Michael McElhaugh will provide a corporate update including an update on our, on our ongoing clinical programs in HBV. Dave will then provide a review of the company's third quarter, 2024 financial results. After our prepared remarks, we will open the call for Q&A before we begin. I'd like to remind you that some of
Q3 2024 Arbutus Biopharma Corp Earnings Call Transcript
7 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers